金纳多对脑梗死患者血液流变学及血管活性物质水平的影响
| 作者: |
1李兆月
1 鄂尔多斯市中心医院保健二科，鄂尔多斯 017000 |
| 通讯: |
李兆月
Email: lizhaoyue151@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2014.05.026 |
摘要
目的：探讨金纳多对脑梗死患者血液流变学及血管活性物质水平的影响。方法：选取2012年2月到 2013年2月我院收治的脑梗死患者74例。根据随机数表法分为实验组和对照组，分别采用金纳多治 疗和常规治疗。比较两组患者的临床疗效、血浆粘度、纤维蛋白原、血浆比粘度、全血还原比粘 度、血细胞比容及ET、TXB2、PGF1α、CGRP水平。结果：实验组总有效率(89.2%)与对照组(67.6%) 之间有明显差异，具有统计学意义(P<0.05)。疗程结束后，实验组血浆粘度为(1.82±0.21)mpa•s， 纤维蛋白原为(2.98±0.59)g/L，血浆比粘度为(1.49±0.15)，全血还原比粘度(7.38±1.79)，血细胞 比容为(0.40±0.07)；对照组血浆粘度为(2.13±0.24)mpa•s，纤维蛋白原为(4.02±0.70)g/L，血浆 比粘度为(1.63±0.19)，全血还原比粘度(7.12±1.63)，血细胞比容为(0.45±0.06)。两组患者的血液 流变学指标与同组治疗前相比均有明显改善，且实验组改善情况更佳。以上差异均具有统计学 意义(P<0.05)。治疗后，实验组的ET为(55.61±18.32)ng/L，TXB2为(65.21±22.03)ng/L，PGF1α 为(74.81±20.93)ng/L，CGRP为(50.09±14.27)ng/L；对照组的ET为(60.01±20.33)ng/L，TXB2为 (72.19±23.67)ng/L，PGF1α为(56.76±19.21)ng/L，CGRP为(23.08±13.76)ng/L。实验组的ET、 TXB2、PGF1α、CGRP，对照组的ET、TXB2与同组治疗前比较均有明显改善，且实验组改善情况 更佳，以上差异均具有统计学意义(P<0.05)。结论： 金纳多能够有效治疗脑梗死，改善患者血液 流变学指标及血管活性物质水平，具有重要的临床价值。
关键词：
金纳多
脑梗死
疗效
血液流变学指标
血管活性物质
The influence of Ginaton on blood rheology and the level of vascular active substances in patients with cerebral infarction
CorrespondingAuthor: LI Zhaoyue Email: lizhaoyue151@163.com
DOI: 10.3978/j.issn.2095-6959.2014.05.026
Abstract
Objective: To discuss the influence of Ginaton on blood rheology and the level of vascular active substances in patients with cerebral infarction. Methods: A total of 74 cases of cerebral infarction patients were chosen from February 2012 to February 2013 in our hospital, and divided into the experimental group and the control group according to the stochastic indicator method, the experimental group was given Ginaton therapy and the control group given conventional therapy. The blood plasma viscosity, fibrinogen, plasma specific viscosity, whole blood reduction than viscosity, hematocrit and ET, TXB2, PGF1 alpha, CGRP levels of two groups were compared. Results: The total effective rate of the experimental group was 89.2% and the control group 67.6%, the difference had statistical significance (P<0.05). After the treatment, the plasma viscosity of the experimental group was (1.82±0.21) mpa•s, fibrin (2.98±0.59) g/L, plasma specific viscosity (1.49±0.15), whole blood reductive viscosity (7.38±1.79), hematocrit (0.40±0.07); the plasma viscosity of the control group was (2.13±0.24) mpa•s, fibrin (4.02±0.70) g/L, plasma specific viscosity (1.63±0.19), whole blood reductive viscosity (7.12±1.63), hematocrit (0.45±0.06). The blood rheology indexes of two groups were improved significantly compared with before treatment, and the improvement of the experimental group was bigger. The improvement differences of two groups were statistically significant (P<0.05). After treatment, the experimental group ET for (55.61±18.32) ng/L, TXB2 for (65.21±22.03) ng/L, PGF1 alpha for (74.81±20.93) ng/L, CGRP (50.09±14.27) ng/L; the control group ET for (60.01±20.33) ng/L, TXB2 for (72.19±23.67) ng/L, PGF1 alpha for (56.76±19.21) ng/L, CGRP (23.08±13.76) ng/L. The ET, TXB2, PGF1 alpha, CGRP of the experimental group and the ET and TXB2 of the control group were improved significantly compared with before treatment, and the improvement of the experimental group was bigger, the differences were statistically significant (P<0.05). Conclusion: Ginaton is effective on treatment of cerebral infarction, and can improve the patient's blood rheological index and vascular active substance level, with important clinical value.